Advanced Adult Primary Liver Cancer Clinical Trial
Official title:
A Phase II Trial of Dasatinib (BMS-354825) in Advanced Hepatocellular Carcinoma
This phase II trial is studying how well dasatinib works in treating patients with advanced liver cancer that cannot be removed by surgery. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
PRIMARY OBJECTIVES:
I. Determine the progression-free survival (PFS) rate and response rate (complete and partial
response) at 4 months in patients with unresectable advanced hepatocellular carcinoma treated
with dasatinib.
SECONDARY OBJECTIVES:
I. Determine the median PFS and overall survival of patients treated with this drug.
II. Assess the toxicity and tolerability of this drug in these patients.
OUTLINE: This is a multicenter study.
Patients receive oral dasatinib twice daily on days 1-28. Courses repeat every 28 days in the
absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed at 4 weeks and then every 3-6
months thereafter.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00787787 -
Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer
|
Phase 2 | |
| Completed |
NCT00052364 -
Oxaliplatin in Treating Patients With Liver Cancer
|
Phase 2 | |
| Completed |
NCT01229111 -
Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers
|
Phase 2 | |
| Completed |
NCT00107536 -
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer
|
Phase 2 | |
| Completed |
NCT02072356 -
Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
|
Early Phase 1 | |
| Completed |
NCT00604721 -
Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer
|
Phase 2 | |
| Completed |
NCT00101036 -
Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery
|
Phase 2 | |
| Completed |
NCT00028496 -
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
|
Phase 1 | |
| Completed |
NCT01766219 -
CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery
|
Phase 1/Phase 2 | |
| Terminated |
NCT00427973 -
AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer
|
Phase 2 | |
| Completed |
NCT00321594 -
Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
|
Phase 1/Phase 2 | |
| Terminated |
NCT00087191 -
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
|
N/A | |
| Completed |
NCT00006016 -
Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
|
Phase 2 | |
| Completed |
NCT01643499 -
Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
|
Phase 1 | |
| Completed |
NCT00639509 -
IMC-A12 in Treating Patients With Advanced Liver Cancer
|
Phase 2 | |
| Completed |
NCT00083226 -
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer
|
Phase 2 | |
| Completed |
NCT00033462 -
Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer
|
Phase 2 | |
| Completed |
NCT01666756 -
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT02119065 -
Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT
|
||
| Recruiting |
NCT02557503 -
Hepatic Arterial Infusion of Oxaliplatin and Fluorouracil Treatment of Advanced Primary Liver Cancer After TACE
|
Phase 4 |